Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.63 [0.6, 0.66]
764 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower progression‐free survival† compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.54 [0.5, 0.6]
1465 participants
High
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with anti‐CTLA4 monoclonal antibodies (high certainty).
1 finding from 1 review
RR 2.47 [2.01, 3.04]
1465 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies may leads to lower toxicity (≥ G3) compared with anti‐CTLA4 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 0.7 [0.54, 0.91]
1465 participants
Low
Overall survival · people with cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to lower progression‐free survival† compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
HR 0.4 [0.35, 0.46]
738 participants
High
Tumour response · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with leads to higher tumour response compared with without anti‐PD1 monoclonal antibodies (high certainty).
1 finding from 1 review
RR 3.5 [2.07, 5.92]
738 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Anti‐CTLA4 monoclonal antibodies with showed no clear difference in toxicity (≥ G3) compared with without anti‐PD1 monoclonal antibodies (low certainty).
1 finding from 1 review
RR 1.57 [0.85, 2.92]
764 participants
Low
Anti‐endotoxin E5 versus placebo, all‐ cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin E5 versus placebo, all‐ cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
It is very uncertain whether monoclonal antibodies changes anti‐endotoxin ‐ HA‐1A versus placebo, all‐cause mortality compared with placebo (very low certainty).
3 findings from 1 review
RR 0.8 [0.54, 1.2]
3 studies · 2668 participants
Very low
RR 1.01 [0.94, 1.09]
6 studies · 4443 participants
Moderate
RR 0.92 [0.79, 1.06]
8 studies · 4676 participants
Low
Anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxins Anti‐LPS versus placebo, all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality ‐ sensitivity analysis · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ low risk of bias studies compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐endotoxin, all‐cause mortality ‐ unclear risk of bias compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ uncertain risk of bias · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anti‐cytokines versus placebo, all‐cause mortality compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.92 [0.86, 0.97]
9 studies · 7893 participants
Moderate
RR 0.91 [0.86, 0.97]
7 studies · 7752 participants
Moderate
RR 0.89 [0.8, 1]
4 studies · 2687 participants
Moderate
Anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies probably leads to lower anticytokine ‐ anti‐TNF‐alpha versus placebo, all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokines ‐ human interleukin‐1receptor antagonist versus placebo, all‐cause mortality · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies showed no clear difference in anti‐cytokines ‐ human interleukin‐1receptor antagonist versus… compared with placebo (moderate certainty).
1 finding from 1 review
Anti‐cytokine, all‐cause mortality ‐ low risk of bias studies · patients with sepsis, severe sepsis, septic shock
Monoclonal antibodies leads to lower anti‐cytokine, all‐cause mortality ‐ low risk of bias studies compared with placebo (high certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.49 [0.39, 0.61]
957 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 3.42 [2.38, 4.92]
1367 participants
High